Methods for determining cost-benefit ratios for pharmaceuticals in Germany
J.‐Matthias Graf v. d. Schulenburg(Hanover College), Wolfgang Greiner(Bielefeld University), Thomas Mittendorf(Leibniz University of Applied Sciences), Christoph Vauth(Leibniz University of Applied Sciences)
Cited by 17
Related Papers
Barriers and Strategies in Guideline Implementation—A Scoping Review
|Healthcare|2016|946
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
German Value Set for the EQ-5D-5L
|PharmacoEconomics|2018|618
Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study
|Quality of Life Research|2010|476
A single European currency for EQ-5D health states
|The European Journal of Health Economics|2003|465